I had an idea when I boughtCastro that human support based around actual user experience was an easy differentiator. I’ve rarely gotten useful answers from support from services I use. I thought if I used my own product every day, read every email and answered it thoughtfully, people would appreciate this, and it would build some degree of loyalty and appreciation.
[…]
However, what I found is this whole thing didn’t work as I thought it would. Sure sometimes we were able to wow customers, particularly when we responded right away with an exact fix for them. But the vast majority of our honest, thoughtful answers were deeply unsatisfactory to users, and it often annoyed them more than anything else.
[…]
Customers email us with confusion about how podcasts work, how the App Store works, how their Mac works, and any number of tangential issues. What tends to happen is the same users do this over and over, and once they find out we answer, the requests get more frequent and more burdensome.
[…]
To the user, any response aside from “Okay, we’re going to build that right now” is meh-to-negative. Various honest responses, such as “I thought about this or tried it in the past and it unfortunately didn’t work very well” are not going to knock their socks off. These just don’t do much in terms of loyalty and rapport.
[…]
Avoiding explanations and specifics tends to get a neutral response and doesn’t suck anyone in or waste too much time. In other words, the best approach for us is what most companies do. Because building loyalty or rapport at the moment something isn’t working and the user is frustrated hasn’t worked. The real positive experience comes when you actually improve the product, so that’s where we’re spending our time.
I have definitely seen all these categories of customer interactions, but I don’t agree with the conclusion. Yes, in the end you want to be improving the product, but I don’t think that’s fully separable from interacting with customers as humans. I’ve found spending time on customer support incredibly valuable for making my products better. Even a lone report of an issue can often lead to a fix and learning something important that has wider implications. It’s also enjoyable and motivational to hear about real people making use of what I’ve built or to turn around someone who started with a negative view. And it seems to help with marketing, too.
I also see a correlation with the apps that I use—the better ones tend to also have good support. That said, I use a podcast app that famously doesn’t offer support. There are different situations, and there’s more than one way to a good product and a successful business.
I do think there’s an art to all this. Not everything can be measured, and there’s more to it than just committing to answering e-mails thoughtfully. You need to set boundaries and steer the interactions to make them productive, efficient, and satisfying for both sides. I’m still learning.
This is what you get from the free with IAP business model: most of your support emails are from freeloaders!
My apps are upfront paid, thus most of my support emails are from customers. I don’t get overloaded with emails, and paid customers are more incentivized to solve issues with you, because they’ve invested money into the app.
I find myself agreeing with you that customer support is valuable and we should do it. But over the years I have also realised that, in a way, being good at support is punishing. I’ll explain[…]
Reset PRAM on Mac is one of those troubleshooting steps that has survived decades of Apple hardware, old support forums and emergency calls to the family member who “knows computers.” The name sounds far more technical than the procedure, which involves restarting an Intel-based Mac while holding four keys.
The reset can help when a Mac remembers the wrong basic settings. It may select an unexpected startup disk, return to an incorrect display resolution, use an unusual sound level or keep other hardware-related preferences that refuse to behave normally.
It is not a speed boost, a deep system repair or a magical cure for every Mac problem. Resetting PRAM will not clear storage, repair a damaged app or make an aging MacBook suddenly feel new. It is a focused fix for a small collection of settings stored outside the usual macOS preferences.
There is also one major limitation: the familiar keyboard shortcut applies only to Intel-based Macs. Apple silicon models handle this memory differently and do not require the same manual reset.
What PRAM Actually Is
PRAM stands for Parameter Random-Access Memory. It was the small amount of memory older Macs used to preserve certain settings while the computer was turned off.
Apple later moved to NVRAM, or nonvolatile random-access memory, but the two names remain closely connected in Mac troubleshooting. Users still search for PRAM reset, while Apple’s current documentation usually calls the procedure an NVRAM or PRAM reset.
The stored information can include the selected startup disk, speaker volume, screen resolution and other low-level settings. When that information becomes incorrect or behaves unpredictably, resetting it allows the Mac to rebuild the relevant preferences.
Nothing dramatic happens to personal data. Documents, photos, apps, emails and user accounts remain untouched. Some settings may return to their defaults, which is the point of the reset.
Reset PRAM on Mac Only When the Symptoms Fit
Reset PRAM on Mac when the problem appears connected to startup or hardware preferences rather than normal app use.
A Mac that repeatedly chooses the wrong startup disk is a good candidate. So is an Intel Mac that starts with an unexpected sound level or returns to a strange display resolution after every restart.
The procedure may also help when the date, time zone or other basic startup settings act strangely, although modern macOS versions usually manage those automatically.
It is less useful when Safari is slow, an app keeps crashing or the Mac is nearly out of storage. Those problems have different causes. Closing apps, installing updates or freeing storage will usually do more than resetting a small bank of startup memory.
The distinction keeps the old troubleshooting step useful without turning it into Mac folklore prescribed for every symptom.
Check Which Mac You Own
Before using the shortcut, confirm whether the Mac has an Intel processor or Apple silicon.
To check:
Apple menu > About This Mac
Look for a line labeled Chip or Processor. An M-series chip identifies Apple silicon. A processor name containing Intel means the traditional reset applies.
This check prevents a common misunderstanding. Holding Option, Command, P and R during startup on an Apple silicon Mac does not perform the old PRAM reset. The shortcut belongs to Intel startup behavior. Apple’s current startup-key guide lists it specifically among key combinations for Intel-based Macs.
Apple silicon Macs check and manage stored startup information through their newer boot system. A normal shutdown and restart is usually the first step when one develops unusual basic behavior.
Image Credit: AppleMagazine
How to Reset PRAM on an Intel Mac
The useful guidance is brief:
Shut down the Mac completely.
Press the power button, then immediately hold:
Option + Command + P + R
Keep the four keys pressed for approximately 20 seconds, then release them and allow the Mac to start normally.
Older Macs may play the startup sound more than once. On some newer Intel models, the Apple logo may appear and disappear during the process.
The timing is the only slightly awkward part. The keys need to be pressed immediately after the Mac begins starting. Waiting until the login window appears is too late.
After the Mac starts, check the setting that caused the problem. The startup disk, volume or display configuration may need to be selected again because the reset cleared the previous preference.
What Changes After the Reset
Most users will notice nothing beyond the original problem hopefully disappearing. The Mac does not present a dramatic confirmation screen or announce that PRAM has been purified.
Instead, a few stored settings may return to their defaults. The speaker volume may change. The preferred startup disk may need to be chosen again. A display may return to its standard resolution. Time-zone information may need a moment to update.
That understated behavior is normal. A successful reset is less like reinstalling macOS and more like asking the Mac to forget a handful of stubborn instructions.
Apple also uses an NVRAM reset as one of the preparation steps for certain Intel Macs before they are sold or transferred, since the procedure clears stored user settings from memory.
Image Credit: Apple Inc.
Why Apple Silicon Macs Do Not Need the Shortcut
Apple silicon changed the Mac startup process along with performance, power efficiency and system security. The older Intel keyboard combination no longer controls the same reset behavior.
For an M-series Mac showing unusual startup settings, begin with a full shutdown rather than repeatedly trying the old shortcut.
Use:
Apple menu > Shut Down
Wait briefly after the screen turns completely black, then turn the Mac back on.
If the problem involves selecting a startup disk or reaching recovery tools, hold the power button while the Mac starts until startup options appear. Apple documents this power-button process as the route into startup options on Apple silicon models. (Apple Support)
That is usually enough guidance for a light troubleshooting article. Recovery, diagnostics and deeper repair steps belong to more serious startup problems, not every incorrect volume level or display setting.
When the Reset Does Nothing
A PRAM reset can fail to change anything because the problem was never stored in PRAM or NVRAM.
A slow Mac may be running too many apps. A browser may have dozens of heavy tabs. A startup disk may be almost full. A damaged cable may cause display problems. A weak battery may cause shutdowns. A broken speaker will not repair itself because four keys were held during startup.
If the symptom continues, return to the problem itself rather than repeating the reset indefinitely.
Check the related setting in System Settings. Install macOS updates. Restart the affected app. Disconnect unnecessary accessories. Confirm that enough storage is available. Persistent hardware behavior may require Apple Diagnostics or professional support.
The reset should be treated as one useful step, not an annual Mac ritual.
Image Credit: AppleMagazine
An Old Mac Fix With a Narrow Purpose
Reset PRAM on Mac remains relevant because Intel models are still in use across homes, schools and businesses. Many continue to work well, and their owners may eventually encounter the sort of odd startup preference that this procedure was designed to clear.
The method is simple, safe for personal files and quick enough to try when the symptoms fit. Its usefulness comes from being specific.
An Intel Mac remembering the wrong startup disk or display setting may benefit. A Mac with an unrelated software or hardware problem will need another answer.
The four-key shortcut has survived because it occasionally solves a strange problem in about 20 seconds. That is a good troubleshooting tool. It just should not be asked to perform miracles.
A white spot on iPad screen can appear as a bright patch that remains visible while browsing, watching videos or using apps. It may be small and easy to ignore at first, then become distracting whenever the screen shows a white, gray or lightly colored background.
The spot may come from a temporary software problem, but a fixed bright area is more commonly connected to the display hardware. Pressure inside the iPad, a damaged backlight layer, display separation or an impact can create uneven illumination that no setting can remove.
Before arranging a repair, a few simple checks can reveal whether the spot belongs to the image being displayed or to the physical screen itself.
What Causes a White Spot on iPad Screen?
A white spot on iPad screen is often described as a bright spot, pressure mark or backlight patch. On iPads with LCD displays, light passes through several internal layers before reaching the glass. When one of those layers becomes damaged, separated or compressed, light can concentrate in one area.
The mark may be more visible against pale backgrounds and almost disappear when the screen displays black or dark content. This is different from a dead pixel, which usually appears as a tiny fixed dot rather than a larger cloudy patch.
Pressure is one possible cause. Carrying an iPad in an overloaded bag, placing heavy objects on it or using a tight case can place stress on the display. A drop may also disturb the internal screen layers without cracking the front glass.
Battery swelling can create similar pressure from inside the device. If the screen is lifting from the frame, the iPad feels unusually warm or the body appears bent, stop using it and seek service. A swollen battery should not be pressed back into place or handled as an ordinary screen defect.
The problem can also appear after a display replacement involving a poorly fitted or lower-quality part. Apple notes that nongenuine displays may produce inconsistent brightness, color or touch behavior.
Image Credit:
Check Whether the Spot Is Really on the Display
Begin by opening several different apps. Look at the spot over a white webpage, a gray Settings screen, a dark photo and a full-screen video. A hardware-related mark normally stays in the same physical location regardless of what appears underneath it.
Rotate the iPad. If the content changes orientation but the bright patch remains in the same part of the glass, the display is the likely cause.
Taking a screenshot provides another useful test. A physical screen defect will not normally become part of the screenshot file.
To take a screenshot on an iPad without a Home button:
Top button + either volume button
To take a screenshot on an iPad with a Home button:
Top button + Home button
Open the screenshot on another device or send it to a trusted computer. If the white spot does not appear there, the image generated by iPadOS is normal and the problem is probably inside the display assembly.
If the mark appears in the screenshot, it may belong to an app, image, accessibility setting or software effect rather than the panel.
Restart Before Assuming Hardware Failure
A restart is worth trying because it clears temporary display and system behavior without affecting personal files. It is unlikely to repair physical backlight damage, but it can eliminate a short-lived graphical problem.
To restart an iPad without a Home button:
Press and hold the top button and either volume button > Drag the power slider > Wait approximately 30 seconds > Hold the top button until the Apple logo appears
To restart an iPad with a Home button:
Press and hold the top button > Drag the power slider > Wait approximately 30 seconds > Hold the top button until the Apple logo appears
After restarting, return to the same pale background and check the area again. A spot that remains fixed is unlikely to be caused by a temporary iPadOS issue.
Image Credit: AppleMagazine
Brightness Can Make the Problem More Visible
Lowering brightness may make a bright patch less distracting, but it does not repair the underlying display. The same applies to Dark Mode, Night Shift and Reduce White Point. These settings can change how noticeable the mark becomes without removing it.
To adjust screen brightness:
Settings > Display & Brightness > Brightness
Test the iPad at several brightness levels. A backlight-related spot may become easier to see as brightness increases. Photographing the screen against a plain background at medium and high brightness can also help document the defect before requesting service.
Avoid pressing or rubbing the affected area. Pressure may temporarily change the appearance, but it can damage the display further. Internet advice suggesting that users massage bright spots out of a panel should be ignored.
Check the Case and Screen Protector
Remove any rigid case that appears unusually tight or has been damaged. A poorly fitted case can place uneven pressure around the frame, particularly if the iPad has been dropped while inside it.
A screen protector normally cannot create a true illuminated patch beneath the display. It can, however, produce bubbles, trapped moisture or reflective marks that resemble a screen defect. Examine the iPad with the display turned off. If the mark is visible on the surface even when the screen is black, the protector or glass may be involved.
Do not remove a properly installed protector solely as an experiment unless the mark clearly appears close to its surface. A bright patch visible only while the display is illuminated usually comes from deeper inside the screen.
When the iPad Needs Repair
A persistent white spot generally requires display service when it remains after restarting and does not appear in screenshots. There is no iPadOS setting that can realign a damaged diffuser, remove internal pressure or repair separated display layers.
Back up the iPad before service so photos, documents and app data remain protected.
To create an iCloud backup:
Settings > your name > iCloud > iCloud Backup > Back Up Now
Apple can inspect the device and determine whether the defect qualifies for warranty coverage, AppleCare service or paid repair. Coverage depends on the device, purchase date, condition and whether the problem resulted from accidental damage.
To check coverage:
Settings > General > AppleCare & Warranty
Apple or an Apple Authorized Service Provider may replace the display assembly or the iPad, depending on the model and available service process. The final repair estimate normally requires inspection.
Image Credit: AppleMagazine
Do Not Ignore Physical Changes
A stable white spot that has not changed for months may remain only a visual annoyance. A spot that is expanding, accompanied by screen lifting or followed by unusual heat needs faster attention.
Stop using the device if the display separates from the enclosure, the iPad becomes visibly swollen or pressure marks spread across the panel. Do not puncture the device, force the display closed or continue charging it unattended.
For an ordinary fixed bright patch, the practical path is simpler: confirm it does not appear in screenshots, restart the iPad, remove any case applying pressure and arrange display service if the mark remains.
A white spot on iPad screen rarely affects the information stored on the device, but it can indicate physical damage that software cannot correct. A brief check can rule out the easy causes. After that, repair is usually more effective than repeatedly changing display settings and hoping the light disappears.
Call forwarding on iPhone is a simple feature with a specific job: it sends incoming calls from your iPhone number to another phone number. That can be useful when you are traveling, using a temporary phone, separating work and personal calls, covering a business line or making sure important calls reach someone else when you cannot answer.
The feature is built into iOS, but it depends on carrier support. Apple notes that call forwarding can be set up on iPhone if cellular service is through a GSM network. If the service uses a CDMA network, users may need to contact the carrier for setup details. That means the option may not appear for every user, every carrier or every plan.
For most supported iPhones, the path is quick:
Settings > Apps > Phone > Call Forwarding
Turn on Call Forwarding, then enter the phone number where calls should be sent. When call forwarding is active, an icon appears in the status bar so the user can see that incoming calls are being routed elsewhere.
Image Credit: AppleMagazine
Call Forwarding on iPhone Sends Calls Elsewhere
Call forwarding on iPhone does not move messages, FaceTime calls, app notifications or voicemail settings by itself. It only redirects standard cellular phone calls. If someone calls your iPhone number, the carrier routes that call to the number you entered.
That distinction is important. If you forward calls to another phone, text messages still arrive on the original iPhone unless other settings or services are involved. FaceTime calls may still ring on Apple devices signed into the same Apple Account. Messaging apps such as WhatsApp, Signal, Telegram or Messenger are unaffected.
Call forwarding is also different from Silence Unknown Callers, Focus modes or Do Not Disturb. Those features control how calls appear or interrupt you. Call forwarding changes where the call goes.
This makes the feature useful in a few common situations. A business owner can send calls to an office line. A traveler can forward calls to a local number. Someone with a damaged iPhone can temporarily send calls to another device. A freelancer can route calls to a partner during time off. A parent can forward calls to a spouse for a short period.
How to Turn On Call Forwarding
To turn on call forwarding:
Settings > Apps > Phone > Call Forwarding
Turn on Call Forwarding
Tap Forward To
Enter the phone number
Go back to save the setting
Use the full phone number, including area code. If forwarding to an international number, include the correct country code. After setting it up, test the feature from another phone. Do not assume it works until a test call rings at the forwarded number.
To turn call forwarding off:
Settings > Apps > Phone > Call Forwarding >Turn off
After turning it off, test again. A quick call from another phone confirms whether incoming calls are back to normal.
If the Call Forwarding menu spins, fails to load or does not save the number, restart the iPhone and check cellular service. If the problem continues, contact the carrier because the setting depends on the carrier network.
Why the Setting May Be Missing
Some users look for call forwarding and cannot find it. That usually means one of three things: the carrier does not expose the feature in iPhone settings, the plan does not support it, or the network requires carrier codes or account-level setup.
Apple’s guide says CDMA users should contact their carrier for call forwarding information. Some carriers also use special dialing codes for forwarding all calls, forwarding when busy, forwarding when unanswered or forwarding when unreachable. Those codes vary by carrier and country, so guessing is not a good idea.
The best path is to check the carrier’s support page or app. Many carriers let users manage forwarding from the account dashboard, especially for business lines or multi-line plans.
If the option is missing, the iPhone is not necessarily broken. The carrier may simply handle forwarding differently.
What Happens to Voicemail
Call forwarding can affect voicemail behavior depending on the carrier and destination number. If the forwarded phone does not answer, the call may go to the voicemail of the forwarded number instead of the original iPhone voicemail. In some cases, carrier rules may still send it back to the original mailbox, but users should not assume that.
This is another reason to test. Call the iPhone from another number, let it ring, and see where the missed call lands. If the goal is to preserve the original iPhone voicemail, carrier support may be needed.
For work numbers, this can be especially important. A forwarded business call going to a personal voicemail greeting can look unprofessional. A personal call going to a shared office voicemail can create privacy problems. Check before relying on it.
Image Credit: Apple Inc.
Call Forwarding and Dual SIM
iPhone users with Dual SIM or eSIM setups should pay attention to which line is being forwarded. A personal line and business line can have separate carrier settings. Forwarding one does not automatically forward the other.
To check lines:
Settings > Cellular >Select the line you want to manage
Then return to:
Settings > Apps > Phone > Call Forwarding
The available settings may vary by carrier and line. If one line supports call forwarding and the other does not, that is usually a carrier difference, not an iPhone problem.
Dual SIM users should also test both numbers separately. Call the personal number, then call the business number, and confirm each behaves as expected.
When Call Forwarding Is Useful
Call forwarding works best when the goal is temporary coverage. It is useful during travel, device repairs, vacations, business handoffs, office moves, event coverage or times when another person needs to answer calls.
It can also help people who use a landline or desk phone during work hours. Calls can be forwarded from the iPhone to the office line, then turned off at the end of the day. The reverse can also work if the carrier supports it.
For small businesses, call forwarding can help avoid missed calls without adding a full phone system. A company can route calls to whoever is available. For individuals, it can be a quick fix when an iPhone battery is failing, a device is being repaired, or cellular reception is better on another phone.
The feature is less ideal as a permanent business phone solution. If multiple people need to answer calls, if calls need menus, if calls need recordings, or if voicemail needs to stay organized, a dedicated phone service may be better.
Privacy and Cost Considerations
Call forwarding may create charges depending on the carrier, plan and destination number. Forwarding calls to an international number can be expensive. Forwarding to another domestic mobile number is usually simpler, but users should still check the plan.
Privacy also deserves attention. Once calls are forwarded, the person or device receiving them may hear personal, business or sensitive conversations meant for the original number. Do not forward calls to a shared phone unless that is intentional.
Before forwarding a work line to a personal number, check company policy. Some organizations do not allow business calls to be routed to unmanaged personal devices.
Image Credit: Freepik
How to Troubleshoot Call Forwarding
If call forwarding does not work, start with the basics. Confirm the iPhone has cellular service. Restart the device. Check that the forwarding number is entered correctly. Turn call forwarding off, wait a few seconds, then turn it on again.
Then test from another phone. A test call is the fastest way to know whether the carrier accepted the setting.
If calls still do not forward, check whether the carrier supports call forwarding through iPhone settings. Some carriers require account-level activation, carrier codes or a business calling feature. If the iPhone setting is missing or stuck, carrier support is usually the right next step.
Also check Focus modes and blocked numbers if the issue is not forwarding but missed calls. A call may fail to ring because of Focus, Silence Unknown Callers, a blocked contact, poor signal or voicemail settings rather than call forwarding.
A Simple Feature Worth Testing
Call forwarding on iPhone is easy to use when the carrier supports it. Open iPhone settings, turn on Call Forwarding, enter the destination number and test it. Turn it off when the temporary need is over.
The feature is most useful when it is deliberate and short-term. It can keep calls moving during travel, repairs, work coverage or busy periods, but it should be checked carefully because voicemail, costs and privacy can change once calls are routed to another number.
The iPhone makes the setting simple. The carrier decides how far that simplicity goes.
AppleCare+ pricing has gone up for new Mac and iPad customers, adding another small cost increase to the Apple ownership equation. According to Bloomberg, Apple has raised monthly and annual AppleCare+ rates for new Mac and iPad plans, with the change applying to new coverage rather than existing plans already active on customer devices.
The increase is modest on paper. Reports indicate Apple has raised monthly AppleCare+ rates by 50 cents and annual plans by $5 for affected Mac and iPad products. For example, AppleCare+ for the 13-inch MacBook Air is now listed at $7.99 per month or $79.99 per year, up from $7.49 per month and $74.99 per year. The Mac mini now starts at $4.49 per month or $44.99 per year, while the 16-inch MacBook Pro costs $15.99 per month or $159.99 per year.
The numbers are not dramatic alone. The context is harder for buyers. Mac and iPad prices have already been under pressure from component costs, financing changes and longer upgrade cycles. AppleCare+ is optional, but for many customers buying expensive laptops and tablets, it is part of the real purchase price.
AppleCare+ Pricing Adds to the Ownership Cost
AppleCare+ pricing is one of those costs many buyers do not fully consider until checkout. The device price gets attention first. Then come storage upgrades, cellular connectivity, keyboard accessories, Apple Pencil, taxes, financing, software subscriptions and protection coverage.
For a MacBook Air, an extra 50 cents per month may not change the decision. For a MacBook Pro, iPad Pro or a family buying multiple devices, the increases add up over time. Annual plans rising by $5 also signal that Apple is comfortable nudging protection costs higher even when the change is small enough to avoid a major backlash.
AppleCare+ remains valuable for users who carry devices daily or depend on them for work. Macs and iPads are portable, expensive and often used in places where accidents happen: classrooms, coffee shops, airports, offices, studios, kitchens and family rooms. A cracked iPad screen or damaged MacBook display can be expensive without coverage.
Apple’s pitch is convenience as much as insurance. AppleCare+ includes priority support, battery service when capacity drops below Apple’s threshold, and reduced service fees for accidental damage. For iPad, AppleCare+ can also cover Apple-branded keyboard accessories and Apple Pencil damage under service-fee terms.
That makes the plan attractive. It also makes the higher price easier for Apple to defend.
Image Credit: Apple Inc.
New Customers Feel the Change First
The latest increase applies to new Mac and iPad AppleCare+ customers. Existing customers with active plans are not the immediate target of the reported change. That distinction helps Apple avoid angering subscribers who already signed up at previous rates, while still lifting revenue from new device buyers.
This approach fits Apple’s broader shift toward recurring coverage. Apple has been moving AppleCare+ further into monthly and annual subscription-style plans, with AppleCare One offering a bundled option for multiple products. The protection plan is no longer only a one-time add-on at purchase. It is increasingly part of Apple’s services layer.
That matters because Apple’s services business depends on recurring payments. AppleCare+ may not get the same attention as iCloud, Apple Music or Apple TV, but it is another way Apple extends the customer relationship beyond the hardware sale. A Mac or iPad purchase becomes not only a device transaction, but also a support and repair subscription.
The price increase strengthens that pattern. A small rise across a large base of new buyers can support services revenue without changing the product lineup.
Mac Buyers Should Compare Plans
Mac buyers now have more reason to compare AppleCare+ options before adding coverage. Apple’s Mac plans vary by model because repair risk and device cost vary. A Mac mini plan starts lower because the device is stationary and less likely to face drops or screen damage. A 16-inch MacBook Pro costs more because it is a high-value portable machine with expensive components.
For a buyer choosing a MacBook Air, AppleCare+ may be easier to justify if the laptop travels daily. Students, journalists, consultants, photographers, editors and business travelers are more exposed to accidental damage than someone who leaves a Mac mini on a desk.
For MacBook Pro buyers, the decision often depends on work dependency. If the Mac is the primary income tool, AppleCare+ can be less about repair math and more about reducing downtime. Access to Apple support and lower repair costs can be worth the subscription if the device is central to daily work.
Still, users should compare the plan cost with their own risk. A careful desktop Mac user may not need the same coverage as a frequent traveler. AppleCare+ is useful, but it should not be automatic for every buyer.
iPad Buyers Face a Different Calculation
iPad AppleCare+ has its own logic because iPads are more physically exposed than Macs in many homes. They are passed between family members, used by children, carried around the house, taken to school, placed in bags and paired with accessories that raise the total cost of ownership.
For iPad Pro and iPad Air buyers, AppleCare+ can make sense because screen repairs and accessory damage can be costly. Apple’s current AppleCare+ terms for iPad include service fees for screen damage, other accidental damage and covered accessories. That can make the plan appealing for users who buy Magic Keyboard, Apple Pencil Pro or a high-end iPad Pro.
The decision becomes more complicated for entry-level iPad buyers. A lower-cost iPad may not justify years of coverage for every user, especially if it stays mostly at home. Families, however, may see the protection differently. An iPad used by children faces more risk than a laptop used carefully by one adult.
The new pricing does not change the core question. It makes the answer slightly more expensive.
AppleCare Products | Warranty Check
AppleCare One Becomes More Relevant
AppleCare One gives Apple another way to soften individual plan increases. The bundle starts at $19.99 per month for up to three eligible products, with additional devices available for $5.99 per month each. It includes AppleCare+ benefits and adds theft and loss coverage for eligible iPhone, iPad and Apple Watch products.
For users with only one Mac or one iPad, AppleCare One may not be the best fit. For users with multiple devices, it can become more attractive as individual plans rise. A person with an iPhone, iPad and Mac may compare three separate AppleCare+ plans against the bundle and find the monthly difference easier to justify.
That is likely part of the strategy. Apple can raise individual plan prices modestly while giving heavier ecosystem users a bundled option. The company has used similar logic across services with Apple One, where the value increases as users subscribe to more Apple products.
The same principle now applies to protection. The deeper a customer is inside Apple’s hardware ecosystem, the easier it becomes to turn support coverage into a monthly bundle.
Small Increase, Larger Signal
AppleCare+ pricing increases may be small, but they arrive during a period when Apple is asking customers to absorb more costs across the ecosystem. Device prices, component pressure, cellular financing, AI hardware demands and service subscriptions all affect the total ownership picture.
The AppleCare+ change fits that pattern. Apple is not dramatically changing the service. It is raising the price slightly while keeping the value proposition intact: lower repair costs, battery service, accidental damage coverage and Apple support.
For buyers, the best response is not panic. It is math. Compare the plan price with the device cost, repair risk, usage pattern and whether multiple Apple products would make AppleCare One more efficient. Someone buying a MacBook Pro for travel may want the protection. Someone buying a Mac mini for a desk may not. A family iPad may be a stronger candidate than a carefully handled personal tablet.
AppleCare+ remains a useful safety net. It is just a slightly more expensive one for new Mac and iPad buyers, and that makes the real cost of the device a little higher than the number on the product page.
A groundbreaking study from Edith Cowan University (ECU) has demonstrated that a structured, midwife-led birth debrief significantly enhances women’s emotional wellbeing postpartum—a development that could redefine standard maternity care. Conducted at Fiona Stanley Hospital, this research tested a standardized conversation guide for birth debriefings, co-designed with midwives, healthcare managers, and maternity advocates to ensure clinical and emotional relevance.
The intervention centers on an emotionally safe, woman-led discussion facilitated by midwifery expertise and therapeutic communication techniques. According to ECU Research Fellow Dr. Kate Buchanan, such debriefings empower women to reflect on and make sense of their childbirth experience, addressing unresolved questions or distress that may persist after hospital discharge. This approach contrasts markedly with typical critical incident debriefs, which focus on clinical review and involve medical staff rather than midwives, and psychological debriefings aimed solely at trauma patients.
Over 100 women participated in the pilot, reporting high satisfaction levels with the midwife-led conversations. Many described the experience as clarifying, validating, and empowering. Participants particularly valued having the discussion with a midwife they already knew, underlining the importance of continuity of care in emotional processing. Dr. Buchanan highlights that midwives, with their holistic understanding of birth as a profound life event, are uniquely positioned to foster this dialogue.
Significantly, the study underscores the potential of midwife-led debriefs to mitigate birth trauma, a condition affecting roughly 30% of women globally. Women who self-identified as having experienced birth trauma rated the opportunity to talk about their birth with a midwife as the most beneficial aspect of the intervention. This therapeutic exchange may offer relief by deepening understanding of the birth events and connecting mothers to further psychological support if needed.
Despite the additional time and resource investment required, hospital management at Fiona Stanley confirmed the intervention’s feasibility and sustainability, emphasizing the importance of allocated time and ongoing training for midwives. The potential long-term benefits, including reductions in mental health burdens and healthcare costs associated with untreated birth trauma, offer compelling justification for integrating debriefs into routine postnatal care.
This innovative research contributes to expanding the global movement toward integrating psychosocial care within maternal health services. By establishing a replicable model that combines clinical expertise with patient-centered communication, the study positions midwife-led birth debriefing as an essential standard in supporting maternal mental health.
The findings were published in BMC Public Health under the title “Co-design and feasibility testing of a midwife-led birth debrief: an implementation science project,” funded by the Women and Infants Research Foundation. As the movement toward holistic postpartum care gains momentum, this study cements the critical role of midwives not only as birth attendants but also as key agents of emotional support in women’s transition to motherhood.
Subject of Research: People Article Title: Co-design and feasibility testing of a midwife-led birth debrief: an implementation science project News Publication Date: 16-Apr-2026 Web References: https://doi.org/10.1186/s12889-026-27342-z Keywords: Maternal mental health, birth trauma, midwife-led intervention, postpartum care, psychosocial support, implementation science
In the ever-evolving field of genomics, a significant leap has been achieved with the introduction of the PGS Browser, a novel public platform designed to transform the way researchers, clinicians, and individuals interact with polygenic scores. Polygenic scores (PGS) are quantitative measures that capture the cumulative effect of numerous genetic variants across the genome, predicting an individual’s predisposition to complex traits and diseases. This new platform promises not just accessibility but also interpretative power, enabling a personalized approach to genomic data that could reshape personalized medicine and risk assessment paradigms worldwide.
At the heart of this transformative tool lies a sophisticated integration of vast genomic datasets, advanced computational algorithms, and user-friendly interfaces. The PGS Browser aggregates polygenic scores derived from an array of large-scale genome-wide association studies (GWAS), providing an unprecedented resource where users can explore the genetic architecture of diverse traits. One of the platform’s most compelling features is its capacity to personalize polygenic risk predictions by incorporating individual genetic data with contextual healthcare analytics, bridging the longstanding gap between raw genetic information and actionable clinical insights.
Traditionally, polygenic scores have been calculated using fixed sets of genetic variants, often constrained by limited population samples or specific ancestral backgrounds. This poses significant challenges regarding the portability and generalizability of these scores across diverse populations. The PGS Browser addresses this limitation head-on by incorporating multi-ancestry datasets and advanced statistical models that recalibrate polygenic scores for diverse genetic ancestries. This opens new horizons in achieving equity in genomic medicine, ensuring individuals from underrepresented populations have access to precise, contextually relevant risk evaluations.
The technical backbone of the PGS Browser involves complex methodologies that include linkage disequilibrium (LD) adjustment, penalized regression frameworks, and machine learning techniques, all optimized for high-throughput and scalable analysis. These computational advances optimize the balance between predictive accuracy and overfitting, a persistent challenge in polygenic score modeling. By dynamically adjusting for confounding genomic features and population stratification, the platform produces risk scores that are both statistically robust and biologically interpretable.
One of the critical innovations within the platform is its interpretability module, designed to unpack the black-box nature of polygenic predictions. Users are not only presented with their personalized polygenic scores but also receive detailed visualizations and annotations explaining the contribution of key genetic loci, biological pathways involved, and potential gene-environment interactions. This level of detail empowers clinicians to make informed decisions and patients to understand the genetic basis of their risks, paving the way for targeted preventative strategies and lifestyle modifications.
From a healthcare perspective, the implications of the PGS Browser extend far beyond academic research. The platform is a strategic tool for genetic counseling, allowing healthcare providers to identify individuals at elevated risk for complex diseases such as cardiovascular disease, diabetes, and certain cancers before clinical symptoms manifest. Early identification through polygenic risk enables preemptive interventions, personalized monitoring, and tailored therapeutic approaches, underscoring a shift from reactive to proactive medicine.
Moreover, the PGS Browser operates with a commitment to transparency and reproducibility, addressing critical concerns in genetic epidemiology. All computational workflows are openly accessible, enabling peer verification and fostering collaborative improvement. The platform also integrates with existing biobank data through standardized protocols, facilitating validation studies and meta-analyses that enhance the reliability of polygenic scores across global cohorts.
A particularly noteworthy aspect of the platform is its potential role in pharmacogenomics. By correlating polygenic scores with drug response phenotypes, the browser could assist in identifying individuals who might benefit from specific medications or require dosage adjustments. This integration with personalized medicine elevates the clinical utility of polygenic scores from risk stratification to therapeutic optimization, highlighting the multi-dimensional impact of genomic data in patient care.
The PGS Browser also bridges the gap between research and public engagement. Designed with intuitive navigation and educational resources, it invites an increasingly genomically literate public to explore their genetic predispositions within a responsible and secure framework. This democratization of genetic information fosters greater awareness and empowerment while maintaining stringent privacy standards, an essential consideration in the era of big data.
In operational terms, the platform boasts scalability features capable of handling millions of individuals’ data concurrently, a necessity given the rapid expansion of genomic databases worldwide. The utilization of cloud-based infrastructures, coupled with containerized computational environments, ensures flexible deployment across various institutional settings while preserving data security and compliance with regulatory frameworks such as GDPR.
From a scientific perspective, the availability of such a public platform catalyzes the discovery of novel gene-trait associations by allowing researchers to perform systematic, large-scale analyses that correlate polygenic scores with phenotypic data. This accelerates the identification of biological mechanisms underlying complex traits, informing subsequent functional studies and therapeutic development pipelines.
Ethical considerations permeate the development and deployment of the PGS Browser. The platform incorporates informed consent modules, guidelines on interpretation limitations, and warnings against deterministic views of genetic risk. By fostering responsible use and interpretation, the platform promotes ethical standards within a field where genetic data can easily be misunderstood or misapplied.
Furthermore, the PGS Browser represents a leap forward in standardizing polygenic score methodologies. Historically, disparate scoring algorithms and variable reporting conventions have hindered comparability across studies. This unified platform offers a harmonized framework that promotes methodological consistency, enabling the scientific community to consolidate findings and build upon a shared foundation.
The cross-disciplinary collaboration manifested in the creation of the PGS Browser highlights the convergence of genetics, bioinformatics, data science, and clinical medicine. This integrative approach is crucial to addressing the complexities of polygenic risk and translating genomic insights into tangible health benefits, marking a pivotal moment in the genomics era.
Looking forward, the PGS Browser sets the stage for continuous evolution. Planned enhancements include integration with longitudinal health records, expansion of trait coverage particularly in psychiatric and neurological domains, and real-time updating as new GWAS data emerge. Such adaptability ensures the platform remains at the forefront of personalized genomics research and application.
In conclusion, the PGS Browser embodies a landmark achievement in the democratization and personalization of polygenic score analysis. By merging rigorous computational techniques with accessible design and ethical mindfulness, it empowers a broad spectrum of users to harness the predictive power of genomic data. This innovation holds transformative potential for healthcare, research, and public understanding, catalyzing a new era in precision medicine where genetic insights are personalized, interpretable, and actionable like never before.
Subject of Research: Development and deployment of a public platform for personalized polygenic score analysis and interpretation.
Article Title: PGS Browser: A Public Platform for Personalized Polygenic Score Analysis and Interpretation.
Article References:
Kolosov, N., Reeve, M.P., Briotta Parolo, P.D. et al. PGS Browser: a public platform for personalized polygenic score analysis and interpretation. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74461-7
In a groundbreaking new study published in Pediatric Research, scientists have unveiled a novel biomarker within mothers’ milk that significantly advances our understanding of secretory activation in mothers of preterm infants. This discovery holds the potential to transform neonatal care by enabling earlier and more precise monitoring of lactation readiness, specifically through assessing sodium content without relying on the traditional sodium-to-potassium (Na:K) ratio. The implications for clinical practice and infant health are profound, especially for premature babies who depend on timely and adequate milk supply.
Secretory activation, the critical transition of the mammary gland to copious milk secretion, has long been a focal point for neonatal healthcare providers. Early and accurate detection of this physiological milestone can dramatically influence infant outcomes by ensuring that premature neonates receive the optimal nutrition needed for growth and immune support. Traditionally, the Na:K ratio in breast milk has served as the primary laboratory marker to signal secretory activation. However, this method presents challenges—samples must be analyzed carefully, and fluctuating electrolyte concentrations often complicate the interpretation, particularly in the dynamic physiology post-delivery.
The study spearheaded by Pei, Meier, Bendixen, and colleagues proposes a compelling alternative: monitoring the sodium (Na) concentration in breast milk independently, without referencing potassium (K) levels. By focusing solely on sodium levels, researchers discovered a more straightforward, faster, and potentially more sensitive biomarker to detect the onset of secretory activation. This shift could overhaul clinical protocols and streamline the path to identifying lactation progress in mothers of preterm infants.
Preterm birth, defined as birth before 37 weeks gestation, is a critical public health challenge affecting millions globally. Infants born prematurely are at elevated risk for complications stemming from immature organ systems, including underdeveloped gastrointestinal tracts that rely heavily on human milk to mitigate risks like necrotizing enterocolitis and infections. Timely secretory activation ensures that mothers can provide milk with adequate volume and composition tailored to meet these vulnerabilities, making the detection of this lactation stage an essential focus.
One of the key findings from the research reveals that sodium concentration alone, measured in mothers’ milk, reliably corresponds with the timing of secretory activation, offering enhanced accuracy over the Na:K ratio. The researchers harnessed cutting-edge biochemical assays and longitudinal sampling of milk from mothers of preterm infants, characterizing electrolyte fluctuations in detail. They demonstrated that sodium levels begin to decrease sharply after secretory activation due to the closure of tight junctions in mammary epithelium, making sodium a robust surrogate marker when potassium is disregarded.
This novel analytical approach holds significant clinical advantages. By simplifying the biomarker assessment to a single electrolyte—sodium—healthcare providers could deploy point-of-care testing devices that quickly inform about lactation status. This immediate feedback is not merely academic; it could empower bedside decision-making, maternal counseling, and targeted interventions such as lactation support or nutritional supplementation tailored to the mother-infant dyad’s needs.
Moreover, the researchers emphasized the particular relevance of this method for mothers of preterm infants, who face complex physiological challenges in initiating and maintaining milk production. The stress of prematurity, along with common maternal health complications, can delay secretory activation, placing these vulnerable infants at nutritional risk. Early detection of such delays via a straightforward sodium measurement could prompt timely remedial strategies, ultimately improving growth trajectories and developmental outcomes.
The molecular and cellular underpinnings lend biological credibility to these findings. Secretory activation involves hormonal cascades, primarily triggered by the precipitous drop in circulating progesterone after placental delivery, alongside rising prolactin levels. This hormonal milieu encourages the closure of mammary tight junctions, reducing sodium passage into milk. Hence, declining sodium concentrations mirror the biochemical shifts indicating functional milk secretion—transforming sodium into a powerful diagnostic proxy.
Beyond the immediate neonatal implications, this study’s methodology aligns with larger trends in personalized medicine and point-of-care diagnostics. By distilling complex physiological events into accessible, quantifiable milk component metrics, the research epitomizes the merging of biochemistry with clinical practicability. As lactation science evolves, such innovations hold promise to optimize maternal-infant health with greater precision and speed.
Nevertheless, the study authors acknowledge potential limitations and areas for further inquiry. The population was focused on mothers of preterm infants, and whether the sodium-only marker applies equally to term deliveries or diverse populations warrants exploration. Additionally, advancing from laboratory assays to user-friendly devices suitable for widespread clinical or even home use will require multidisciplinary collaboration in engineering, biochemistry, and healthcare delivery.
Intriguingly, the research opens doors to investigating how other milk components—such as immunoglobulins, hormones, or other electrolytes—could synergize with sodium assessment to map lactation physiology more comprehensively. Future studies might expand this framework to encompass not just secretory activation timing but also milk quality, volume forecasting, and infant growth correlation, painting a more holistic picture of lactation dynamics.
The implications extend beyond immediate clinical management. For neonatologists and lactation consultants, a reliable and rapid biomarker offers a potent tool for enhancing support programs, tailoring interventions, and potentially improving breastfeeding success rates and duration, especially in the fragile realm of neonatal intensive care. With breastfeeding recognized globally as a cornerstone of infant health, innovations like these resonate far across public health landscapes.
In sum, Pei and colleagues’ work represents a pivotal advancement in lactation science and neonatal nutrition. By elucidating the power of sodium measurements without the confounding Na:K ratio, they have charted a path toward more streamlined, accurate, and clinically actionable monitoring of secretory activation in mothers of preterm infants. This biomarker could become a vital asset in neonatal care, ensuring the earliest possible identification of lactation onset and facilitating optimal support for both mother and child during a crucial period.
As this research garners attention, it is poised to influence future guidelines and inspire technological innovation in lactation monitoring. The prospect of employing simple sodium assays in diverse care settings—from tertiary hospitals to community clinics—heralds a democratization of lactation science, empowering more mothers to achieve successful breastfeeding outcomes, regardless of prematurity challenges.
The cascade of benefits from this research is already rippling through the scientific and medical communities. Improved neonatal nutrition, reduced complications from feeding delays, and enhanced maternal confidence all emerge from a seemingly small shift in how we understand and measure breast milk composition. Such breakthroughs underscore the power of focused biochemical insight to generate transformative healthcare innovations.
Looking forward, collaborations between researchers, clinicians, and technologists will be essential in translating this discovery into effective clinical tools. As innovation speeds up, the integration of rapid sodium tests into neonatal intensive care workflows could soon become standard, ensuring that no preterm infant is left behind in the race toward optimal growth and development. This study not only advances science but also embodies a vital step toward better health outcomes worldwide.
Subject of Research: Secretory activation in mothers of preterm infants as detected through sodium concentration measurements in breast milk.
Article Title: Mothers’ milk Na without Na:K ratio detects secretory activation in mothers of preterm infants.
Article References:
Pei, Q., Meier, P.P., Bendixen, M.M. et al. Mothers’ milk Na without Na:K ratio detects secretory activation in mothers of preterm infants. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05206-x
In the ever-evolving quest to enhance neonatal nutrition, the use of bovine colostrum as a fortifier for human milk has emerged as a topic of significant scientific intrigue. A recent study published in Pediatric Research by Lapillonne, Sartorius, and Moltu delves into the complex biology underpinning this approach, highlighting both its promising potential and the challenges that have thus far tempered its clinical impact. As premature and low-birth-weight infants demand optimal nutritional strategies to support rapid growth and immune development, the notion of augmenting human milk with bovine colostrum embodies a sophisticated interplay of biochemical and immunological factors that warrants closer examination.
Colostrum, the initial secretion from the mammary glands following birth, is a nutrient-dense fluid packed with bioactive compounds including immunoglobulins, growth factors, antimicrobial peptides, and cytokines. Bovine colostrum, in particular, has been extensively researched for its rich composition and ability to promote gut maturation and systemic immunity in various animal models. Translating this biology to human neonates, especially those reliant on human milk fortification, has generated enthusiasm given the colostrum’s capacity to potentially fill nutritional and protective gaps that donor milk or formula might not address.
However, the biological complexity that makes bovine colostrum attractive also poses significant hurdles when applied to human infants. The immunological components tailored to bovine pathogens and development may not fully align with human neonatal needs, raising concerns about immune compatibility and allergenic reactions. Furthermore, the precise molecular interactions of bovine bioactive molecules within the human gastrointestinal environment remain insufficiently understood, especially concerning enzymatic digestion, absorption efficiency, and systemic bioavailability.
The study rigorously assessed clinical trials incorporating bovine colostrum fortification in preterm infants, revealing a perplexing dichotomy: despite robust mechanistic evidence supporting enhanced gut barrier function and anti-inflammatory effects in vitro, the anticipated improvements in measurable clinical outcomes such as growth velocity, incidence of necrotizing enterocolitis (NEC), and sepsis rates have remained elusive. This disconnect signals the intricate nature of neonatal physiology where multifactorial factors including genetic makeup, gut microbiota composition, and perinatal interventions collectively influence health trajectories.
One particularly enlightening aspect of the research highlights the variability in colostrum sourcing and processing methods that significantly affect its biological efficacy. Pasteurization and freeze-drying, necessary for safety and preservation, inadvertently diminish key immunoglobulins and growth factors, potentially moderating the fortifier’s beneficial attributes. Standardizing manufacturing protocols and establishing stringent quality control measures are identified as pivotal steps toward ensuring consistent clinical performance.
Moreover, the study emphasizes the critical importance of dosing regimens and timing. Infants’ developmental stage at the commencement of bovine colostrum supplementation appears to be a determinant of response, with early postnatal windows offering theoretically greater receptiveness to bioactive molecules. In contrast, delayed administration may coincide with the maturation of endogenous immune functions, reducing the relative impact of external fortification. Tailored strategies considering individual patient profiles thus emerge as logical pathways for optimizing outcomes.
The authors also explore the potential of combining bovine colostrum with prebiotics and probiotics to synergistically modulate the neonatal gut milieu. Such combinatorial approaches aim to harness the protective effects on epithelial integrity and microbial colonization, which together contribute to mitigating inflammatory cascades implicated in NEC and other morbidities. Nonetheless, the multifaceted interactions within the gut ecosystem complicate definitive attributions of efficacy to colostrum alone.
From a translational science perspective, the review underscores the pressing need for advanced analytical techniques to dissect the bioactive constituents at molecular resolution. High-throughput proteomics, metabolomics, and immunophenotyping stand out as crucial modalities to map how bovine colostrum components survive digestion, interact with gut receptors, and influence systemic immunomodulatory pathways. These insights promise to illuminate actionable biomarkers predictive of clinical benefit.
The ethical dimension represented by parental consent and safety assurances also permeates the discussion. The vulnerability of neonatal populations necessitates rigorous regulatory scrutiny and transparent communication regarding experimental fortification protocols. In this context, elucidating long-term neurodevelopmental implications remains a key research frontier, with current data insufficient to fully affirm or dismiss the safety profile of bovine colostrum fortifiers.
Delving deeper into immunology, the authors discuss the role of bovine-derived lactoferrin, a multifunctional glycoprotein known for its antimicrobial and anti-inflammatory properties. Interestingly, comparative analyses suggest human lactoferrin differs structurally and functionally, raising questions about substitution efficacy. Enzymatic degradation patterns within the infant gut further complicate the retention of lactoferrin activity post-ingestion, thereby influencing fortifier design considerations.
The metabolic dimension is analyzed with reference to the growth factors contained in colostrum such as insulin-like growth factor-1 (IGF-1) and transforming growth factor-beta (TGF-β). These peptides orchestrate cellular proliferation, differentiation, and tissue repair processes crucial to organ development. Yet, their therapeutic window and dosage thresholds when introduced exogenously via bovine sources remain ambiguous, emphasizing the necessity for dose-escalation studies to delineate optimum usage.
In addition to physiological effects, the review addresses the microbiological safety concerns associated with bovine colostrum, acknowledging the potential for zoonotic pathogen transmission despite stringent pasteurization. The imperative for developing pathogen-free colostrum derivatives or recombinant bioactivity mimetics emerges as a forward-looking solution to mitigate infectious risks in vulnerable neonatal cohorts.
While clinical endpoints have yet to definitively prove the superiority of bovine colostrum fortification over conventional methods, the biological rationale remains compelling. The authors call for multicenter, randomized controlled trials with sufficient statistical power and standardized protocols to rigorously evaluate clinical efficacy. Integrative data modeling combining clinical, molecular, and microbiome parameters is proposed to unravel the nuanced interplay dictating infant outcomes.
Ultimately, this comprehensive analysis accentuates a critical insight: bovine colostrum embodies a biologically rich but clinically complex candidate for human milk fortification. Its utility traverses a balance between remarkable theoretical benefits and practical limitations identified through current evidence. The path forward lies in precision neonatal nutrition strategies that leverage biotechnological advances, harmonize safety with efficacy, and address individual variability.
The publication by Lapillonne and colleagues thus provides a seminal synthesis that challenges researchers and clinicians alike to rethink the paradigms underpinning neonatal fortification. It underscores the need for interdisciplinary collaboration encompassing neonatology, immunology, nutrition science, and bioprocess engineering. By refining translational pipelines and embracing sophisticated analytical methodologies, the promise of bovine colostrum as a transformative human milk fortifier may yet be realized in the coming years.
This nuanced narrative invites the scientific community to maintain a balanced perspective—acknowledging both the groundbreaking biological insights and the tempered clinical realities—to forge innovative solutions for optimizing neonatal health through advanced milk fortification technologies.
Subject of Research:
Bovine colostrum as a human milk fortifier in neonatal nutrition, focusing on its biological properties, clinical application, and challenges.
Article Title:
Bovine colostrum as a human milk fortifier: promising biology, elusive clinical benefit.
Article References:
Lapillonne, A., Sartorius, V. & Moltu, S.J. Bovine colostrum as a human milk fortifier: promising biology, elusive clinical benefit. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05248-1
Physicians and researchers at the Netherlands Cancer Institute have unveiled a groundbreaking artificial intelligence (AI) model that fundamentally reshapes how treatment responses in pleural mesothelioma—a notoriously challenging cancer—are evaluated. This model, called ARTIMES, excels beyond traditional clinical methods, surpassing expert human judgment in accuracy and efficiency. By precisely measuring the entire tumor volume instead of relying on conventional diameter-based assessments, ARTIMES promises to revolutionize patient care and accelerate clinical research in this difficult-to-treat disease.
Pleural mesothelioma poses unique diagnostic challenges because it develops as a thin, irregular layer along the lining of the lungs rather than forming discrete masses. This morphology renders existing international standards like the RECIST (Response Evaluation Criteria in Solid Tumors) inadequate. RECIST depends primarily on simple diameter measures, which poorly represent the tumor’s true progression or regression in mesothelioma’s diffuse growth pattern. Clinicians have expressed frustration and uncertainty in evaluating treatment efficacy using these parameters, highlighting a pressing need for a more refined and reliable approach.
To address these limitations, an interdisciplinary team of AI scientists, radiologists, and pulmonologists collaborated at the Netherlands Cancer Institute. Leveraging an extensive dataset comprising over 11,000 computed tomography (CT) scans from more than 2,000 patients across 121 hospitals worldwide, they developed ARTIMES, an AI-driven volumetric response evaluation tool. Unlike humans, who face near-impossible challenges in manually delineating tumor boundaries at the pixel level on complex images, ARTIMES can effortlessly segment entire tumors and calculate their true volume with exceptional precision.
Pulmonologist Sjaak Burgers emphasizes that ARTIMES advances clinical practice by eliminating tedious and error-prone manual tumor assessments. While verifying the AI’s output remains essential, the review process is far less labor-intensive. This reduces interobserver variability and enables clinicians to obtain more consistent and objective insights into tumor dynamics. The ability to evaluate the full tumor burden rather than a single diameter mark dramatically increases sensitivity for detecting true positive or negative treatment responses.
The scientific community is witnessing a milestone with ARTIMES being the first AI model worldwide to demonstrably outperform clinicians in assessing treatment outcomes for pleural mesothelioma. Kevin Groot Lipman, lead author and technical physician, highlights that their study, published in The Lancet Oncology, cements AI’s potential to become an integral clinical decision support tool. Importantly, ARTIMES enhances rather than replaces physician judgment, interfacing smoothly into existing workflows while enabling rapid, data-driven decision-making.
Beyond measuring tumor volume, the researchers have undertaken the critical task of integrating ARTIMES measurements into actionable clinical guidelines. Since knowing the tumor size alone does not dictate specific treatment changes, these criteria empower pulmonologists to determine when to modify or cease therapies. This synergy ensures that patients receive individualized care tailored to their tumor behavior patterns, reducing exposure to ineffective treatments and unnecessary side effects while optimizing healthcare resources.
One of ARTIMES’s most transformative capabilities is its ability to detect non-response to therapy earlier than ever before. This timely recognition allows physicians to pivot treatment plans sooner, offering patients alternative therapeutic avenues or sparing them from futile and potentially harmful continuation of ineffective regimens. The combination of predictive accuracy and clinical oversight represents a major leap forward in precision oncology for pleural mesothelioma patients.
Currently, EU regulations restrict ARTIMES’s use exclusively to the Netherlands Cancer Institute under an in-house exemption, given that the model was developed internally. Nonetheless, the research team is actively pursuing regulatory approval to deploy ARTIMES globally in other hospitals. There is hopeful anticipation surrounding proposed EU frameworks aimed at streamlining the certification process for AI-enabled medical devices, which could accelerate widespread adoption and patient benefit.
The advent of ARTIMES is poised to deliver a shockwave across oncology fields by demonstrating the tangible superiority of AI over human evaluators in complex tumor assessments. To foster transparency and collaborative innovation, the Netherlands Cancer Institute has made the mesothelioma AI model publicly accessible online, enabling researchers worldwide to explore and extend its applications. This open science approach is expected to catalyze new studies and adaptations for other tumor types with challenging morphologies.
Already, the NKI team is extending their AI methodologies to address lung cancer and brain metastasis tumor evaluations. The success of ARTIMES signals the dawn of a new epoch in oncological imaging, where volumetric and morphological complexities that previously hindered precise quantification become tractable. Such breakthroughs unlock significant potential to enhance clinical trial design by furnishing robust, reproducible endpoints that more faithfully capture therapeutic impact.
Clinical trials for novel treatments stand to gain markedly from ARTIMES’s introduction. Using data from eight distinct trials, the research team validated that AI-guided volumetric criteria yield significantly improved accuracy relative to traditional RECIST assessments. This refined precision enables better evaluation of an investigational drug’s efficacy, ultimately accelerating regulatory approval timelines and facilitating faster patient access to promising therapies.
In summary, ARTIMES exemplifies how synergistic integration of AI and clinical expertise can surmount longstanding challenges in tumor measurement. By transitioning from simplistic unidimensional diameter metrics to comprehensive volumetric analysis, this technology brings unprecedented clarity and confidence to oncological decision-making. As this AI model becomes more widely disseminated and refined, it heralds a paradigm shift in cancer treatment evaluation, with rippling benefits for patients, clinicians, and research worldwide.
Subject of Research: People
Article Title: Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
References:
Groot Lipman K, Burgers S, et al. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study. The Lancet Oncology, 2026.
In recent years, the advent of artificial intelligence (AI) has reshaped the landscape of medical research and clinical practice, ushering in an era where machines replicate—and increasingly surpass—human cognitive abilities in various domains. Among the most intriguing developments is the capability of AI systems to assimilate vast troves of real-world data, allowing algorithms to accurately recognize complex patterns within clinical environments. This includes the identification of intricate pathological features, accurate labeling of disease states, and support in making critical healthcare decisions. Central to this revolution is the notion of synthetic data generation, a cutting-edge technology poised to tackle longstanding barriers impeding medical innovation, particularly in the realm of gastrointestinal (GI) medicine.
Synthetic data generation refers to the process through which artificial datasets are created by AI algorithms, mimicking the statistical properties and underlying structures of real-world clinical data without exposing sensitive patient information. This technique promises to solve two critical challenges: preserving patient privacy and reducing the often exorbitant costs and logistical complexities associated with curating and annotating healthcare datasets. By producing realistic, unbiased, and privacy-preserving synthetic data, researchers and clinicians could unlock unprecedented opportunities for training sophisticated AI models and improving clinical decision support systems tailored to gastrointestinal health.
In the context of gastrointestinal diseases, where early detection and precise diagnosis are often paramount, synthetic data offers a transformative potential. GI disorders encompass a broad spectrum of conditions, such as inflammatory bowel disease, colorectal cancer, and liver cirrhosis, each demanding nuanced understanding and timely intervention. Traditional approaches to gathering data for AI training encounter significant roadblocks, including patient consent restrictions, heterogeneous data quality, and the inherent rarity of some disease presentations. Generating synthetic equivalents of such data not only bridges these gaps but also enables the continuous refinement of diagnostic algorithms through virtually unlimited and diverse data augmentation.
From a technical standpoint, generating high-fidelity synthetic GI data entails leveraging advanced generative models, such as Generative Adversarial Networks (GANs), Variational Autoencoders (VAEs), and diffusion models. GANs, for example, pit two neural networks against each other in a zero-sum game—the generator strives to create realistic data indistinguishable from original datasets, while the discriminator attempts to detect artificiality. This adversarial process gradually improves the quality of synthetic outputs, rendering them increasingly suitable for downstream clinical applications. However, the GI domain presents unique challenges due to the complexity and variability inherent in endoscopic images, histopathological slides, and multi-omics data.
A profound technical hurdle lies in ensuring that synthetic gastrointestinal datasets retain clinical validity and biological relevance. Unlike generic image synthesis, medical data synthesis must preserve subtle yet critical diagnostic details, such as mucosal texture alterations, microvascular patterns, and lesion morphology. Obtaining this level of fidelity mandates incorporating domain-specific constraints and annotation-guided synthesis protocols. Furthermore, the synthetic data must demonstrate robustness to common sources of variability: differences in imaging devices, procedural inconsistencies, and patient-specific anatomical variations. Without these safeguards, downstream AI models risk being trained on data that poorly represents true clinical scenarios and yield unreliable predictions.
Another pivotal aspect of using synthetic data in gastrointestinal medicine is its contribution to overcoming privacy legislation hurdles like HIPAA or GDPR. Traditional anonymization methods risk compromising data utility or may be insufficient in preventing re-identification attacks. Conversely, by training generative models on real patient data and producing artificial yet representative datasets, synthetic data generation preserves privacy inherently, as no direct personal identifiers or actual patient samples are included. This feature fosters a more open collaboration across institutions and research groups, catalyzing the development of multipurpose AI-driven tools capable of detecting early-stage GI malignancies, monitoring disease progression, and predicting therapeutic responses.
Despite the tremendous promise of synthetic data, translating this innovation from research laboratories to clinical workflows demands meticulous validation and regulatory compliance. Clinical decision support systems powered by synthetic data-driven AI must undergo rigorous testing against gold standards to verify their safety and effectiveness. Interpretability also remains a significant concern, as clinicians must trust and understand AI recommendations to incorporate them confidently in patient care. Efforts to integrate synthetic data into regulatory frameworks, combined with transparent reporting of generative model performance metrics, will be crucial to achieving widespread clinical acceptance.
Synthetic data not only enhances diagnostic AI but opens new frontiers for medical education and professional training in gastroenterology. Trainees often face limited exposure to rare or complex cases, which impedes skill acquisition and confidence-building. High-quality synthetic datasets can provide diverse and unlimited case simulations, including pathologies that might be encountered infrequently but require high diagnostic acumen. This approach supports immersive, hands-on learning without compromising patient safety or privacy, helping to shape the next generation of gastroenterologists equipped with AI-enhanced diagnostic abilities.
Moreover, the adoption of synthetic data dovetails with the broader trend of precision medicine and personalized healthcare. By complementing real patient data with synthetic counterparts generated under controlled conditions, AI models can better capture the heterogeneity of gastrointestinal diseases, including genetic, environmental and lifestyle factors. This richer informational substrate empowers clinicians to tailor interventions more precisely, leading to improved patient outcomes, reduced adverse effects, and optimized resource utilization. Synthetic data thus acts as a cornerstone technology in enabling AI systems to realize their full potential in individualized care pathways.
Nevertheless, emerging research highlights several critical challenges that warrant attention for synthetic data to reach its full utility. One major issue is preventing the inadvertent introduction of bias during data synthesis, which could propagate and amplify healthcare disparities if not carefully addressed. Ensuring equitable representation across demographics, comorbidities, and clinical settings is imperative. Additionally, synthetic data generation must grapple with the potential for overfitting or hallucination, where models produce plausible yet clinically inaccurate artifacts. Developing rigorous validation metrics, cross-institutional benchmarking, and consensus guidelines will be necessary steps to mitigate these risks effectively.
In parallel, fostering multidisciplinary collaboration among clinicians, computer scientists, data privacy experts, and ethicists will accelerate the adoption of synthetic data paradigms. This convergence of expertise will enable the design of sophisticated pipelines that uphold ethical standards, comply with legal mandates, and optimize clinical relevance. It will also stimulate innovation in enhancing generative model architectures, integrating multi-modal data sources, and streamlining model deployment within real-time endoscopy or pathology workflows.
Reflecting on the current trajectory, the era of synthetic data in gastrointestinal medicine signals a paradigm shift from data scarcity and privacy constraints toward unprecedented data abundance and accessibility. As AI algorithms evolve and healthcare systems embrace digital transformation, synthetic data will be pivotal in democratizing access to high-quality datasets, unleashing creativity in algorithm development, and fostering robust, scalable solutions for early disease detection and personalized treatment. The implications extend beyond GI diseases, serving as a blueprint for AI-driven clinical innovation across medical specialties.
In conclusion, the synthesis of artificial yet clinically meaningful datasets represents one of the most promising frontiers in AI and medicine. While significant challenges remain—technical, ethical, and regulatory—the momentum and early successes within gastrointestinal medicine are compelling. Future research should focus on refining generative approaches, validating AI models trained on synthetic data across diverse populations, and embedding these technologies seamlessly into clinical practice. Ultimately, the judicious application of synthetic data holds the key to unlocking the full transformative power of artificial intelligence for improved patient care and health system efficiency worldwide.
Subject of Research: Synthetic data generation and its application in gastrointestinal medicine.
Article Title: Synthetic data generation: challenges and perspectives for gastrointestinal medicine.
Article References:
Gatoula, P., Iakovidis, D.K., Diamantis, D.E. et al. Synthetic data generation: challenges and perspectives for gastrointestinal medicine. Nat Rev Gastroenterol Hepatol (2026). https://doi.org/10.1038/s41575-026-01216-6
In a bid to dismiss a lawsuit over xAI’s polluting gas turbines, the Justice Department claimed the company is integral to military operations—including the Iran War.
Login
